All patients
HER2 positive
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
la/mBC - HER2 positive - 2nd Line (L2), HER2 inhibitor vs. HER inhibitor, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results HER2CLIMB, 2020 0.66 [0.50; 0.88]
LUX-Breast 1, 2016 1.48 [1.12; 1.95]
NALA, 2020 0.88 [0.72; 1.07]
NALA (brain metastases), 2020 0.90 [0.59; 1.38]
0.94 [0.67 ; 1.31 ] HER2CLIMB, 2020, LUX-Breast 1, 2016, NALA, 2020, NALA (brain metastases), 2020 4 82% 1,842 moderate not evaluable progression or deaths (PFS)detailed results HER2CLIMB, 2020 0.54 [0.42; 0.70]
HER2CLIMB (patients with brain metastases), 2020 0.48 [0.34; 0.68]
LUX-Breast 1, 2016 1.10 [0.86; 1.41]
NALA, 2020 0.76 [0.63; 0.92]
NALA (brain metastases), 2020 0.66 [0.41; 1.06]
0.69 [0.51 ; 0.92 ] HER2CLIMB, 2020, HER2CLIMB (patients with brain metastases), 2020, LUX-Breast 1, 2016, NALA, 2020, NALA (brain metastases), 2020 5 81% 2,001 moderate not evaluable DORdetailed results NALA, 2020 0.50 [0.33; 0.75]
NALA (brain metastases), 2020 0.47 [0.12; 1.88]
0.50 [0.34 ; 0.73 ] NALA, 2020, NALA (brain metastases), 2020 2 0% 722 moderate not evaluable objective responses (ORR)detailed results LUX-Breast 1, 2016 1.04 [0.71; 1.52]
NALA (brain metastases), 2020 1.02 [0.37; 2.80]
1.04 [0.73 ; 1.48 ] LUX-Breast 1, 2016, NALA (brain metastases), 2020 2 0% 576 moderate not evaluable AE leading to treatment discontinuation (any grade)detailed results HER2CLIMB, 2020 1.92 [0.77; 4.80]
1.92 [0.77 ; 4.80 ] HER2CLIMB, 2020 1 0% 601 NA not evaluable Anaemia AE (grade 3-4)detailed results NALA (brain metastases), 2020 0.48 [0.02; 14.79]
0.48 [0.02 ; 14.79 ] NALA (brain metastases), 2020 1 0% 99 NA not evaluable Asthenia AE (grade 3-4)detailed results NALA (brain metastases), 2020 0.31 [0.03; 3.12]
0.31 [0.03 ; 3.12 ] NALA (brain metastases), 2020 1 0% 99 NA not evaluable Back pain AE (grade 3-4)detailed results NALA (brain metastases), 2020 0.98 [0.02; 50.38]
0.98 [0.02 ; 50.38 ] NALA (brain metastases), 2020 1 0% 99 NA not evaluable Constipation AE (grade 3-4)detailed results NALA (brain metastases), 2020 0.98 [0.02; 50.38]
0.98 [0.02 ; 50.38 ] NALA (brain metastases), 2020 1 0% 99 NA not evaluable Decreased appetite AE (grade 3-4)detailed results NALA (brain metastases), 2020 0.98 [0.06; 16.11]
0.98 [0.06 ; 16.11 ] NALA (brain metastases), 2020 1 0% 99 NA not evaluable Diarrhoea AE (grade 3-4)detailed results NALA (brain metastases), 2020 2.48 [0.79; 7.77]
2.48 [0.79 ; 7.77 ] NALA (brain metastases), 2020 1 0% 99 NA not evaluable Fatigue AE (grade 3-4)detailed results NALA (brain metastases), 2020 0.98 [0.13; 7.24]
0.98 [0.13 ; 7.24 ] NALA (brain metastases), 2020 1 0% 99 NA not evaluable Headache AE (grade 3-4)detailed results NALA (brain metastases), 2020 0.98 [0.02; 50.38]
0.98 [0.02 ; 50.38 ] NALA (brain metastases), 2020 1 0% 99 NA not evaluable Nausea AE (grade 3-4)detailed results NALA (brain metastases), 2020 0.64 [0.10; 4.00]
0.64 [0.10 ; 4.00 ] NALA (brain metastases), 2020 1 0% 99 NA not evaluable Palmar–plantar erythrodysesthesia syndrome AE (grade 3-4)detailed results NALA (brain metastases), 2020 0.98 [0.29; 3.27]
0.98 [0.29 ; 3.27 ] NALA (brain metastases), 2020 1 0% 99 NA not evaluable Pyrexia AE (grade 3-4)detailed results NALA (brain metastases), 2020 0.48 [0.02; 14.79]
0.48 [0.02 ; 14.79 ] NALA (brain metastases), 2020 1 0% 99 NA not evaluable Rash AE (grade 3-4)detailed results NALA (brain metastases), 2020 0.48 [0.02; 14.79]
0.48 [0.02 ; 14.79 ] NALA (brain metastases), 2020 1 0% 99 NA not evaluable Stomatitis AE (grade 3-4)detailed results NALA (brain metastases), 2020 0.48 [0.02; 14.79]
0.48 [0.02 ; 14.79 ] NALA (brain metastases), 2020 1 0% 99 NA not evaluable Vomiting AE (grade 3-4)detailed results NALA (brain metastases), 2020 0.98 [0.06; 16.11]
0.98 [0.06 ; 16.11 ] NALA (brain metastases), 2020 1 0% 99 NA not evaluable Weight decreased AE (grade 3-4)detailed results NALA (brain metastases), 2020 0.98 [0.06; 16.11]
0.98 [0.06 ; 16.11 ] NALA (brain metastases), 2020 1 0% 99 NA not evaluable 0.2 5.0 1.0 relative treatment effect www.metaEvidence.org 2024-06-29 21:33 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 317
- treatments: 702,1313,498,1314,368,1301,1412,1298,1299,1334,1332,1303,1325,1320,1305,1300,1429,1324,1335,1307,1322,1319,718
